MedTrace Logo

A Comparison of PF708 and Forteo in Osteoporosis Patients

NCT03002428 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 181

Last updated 2018-05-23

No results posted yet for this study

Summary

The purpose of this study is to compare the effects of two teriparatide products, PF708 and Forteo, in patients with osteoporosis.

Conditions

Interventions

DRUG

Teriparatide (PF708)

Subcutaneous injection

DRUG

Teriparatide (Forteo)

Subcutaneous injection

Sponsors & Collaborators

  • Pfenex, Inc

    lead INDUSTRY

Principal Investigators

  • Hubert C Chen, MD · Pfenex, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2018-05-31
Completion
2018-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03002428 on ClinicalTrials.gov